2-DG (2-Deoxy-D-glucose) Clinical Trials

Size	Price	Qty
500mg	USD 147
1g	USD 239

Clinical Trials

Numerous clinical trials spanning Phase 1 to Phase 3 evaluate the therapeutic and diagnostic potential of 2-Deoxy-D-glucose (2-DG), sponsored by pharmaceutical entities such as Threshold Pharmaceuticals and Hoffmann-La Roche, as well as academic institutions like Rutgers University. Research focuses on oncological conditions—including prostate, breast, lung, and intracranial neoplasms—alongside non-oncological disorders such as epilepsy, Alzheimer's disease, and pulmonary hypertension. While several trials have achieved completed recruitment status, others have been marked as terminated or withdrawn.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06375772	TERMINATED	Acute Nasopharyngitis	G.ST Antivirals GmbH	2024-04-02	PHASE2
NCT05605301	COMPLETED	Epilepsy; Seizure	University of Virginia	2022-09-02	PHASE2
NCT02489604	TERMINATED	Neuroendocrine Tumors	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	2013-12	PHASE2
NCT05314933	COMPLETED	Acute Nasopharyngitis	G.ST Antivirals GmbH	2022-03-03	PHASE1
NCT00002981	COMPLETED	Prostate Cancer	Memorial Sloan Kettering Cancer Center	1997-01
NCT02469922	COMPLETED	Malignant Neoplasm of Head and Neck; Locally Advanced Malignant Neoplasm	Center Eugene Marquis	2014-06
NCT02208544	COMPLETED	Thyroid Nodule; Thyroid Neoplasms	Radboud University Medical Center	2015-07-16
NCT02317783	TERMINATED	Breast Cancer	University of Utah	2018-01-31	PHASE2
NCT01917136	COMPLETED	Pulmonary Hypertension	University of Pennsylvania	2013-08	PHASE2
NCT02558140	Completed	Neoplasms	Hoffmann-La Roche	2015-10-11	Phase 1
NCT00708045	COMPLETED	Cancer	University of Utah	2007-05-09	PHASE1
NCT00813566	COMPLETED	Brain Tumors; Cancer	University of Utah	2010-11-12	PHASE1
NCT01246869	TERMINATED	Brain Cancer	University of Utah	2013-03-27	PHASE1
NCT01998841	Completed	Alzheimer''s Disease	Genentech Inc.\|Banner Alzheimer''s Institute\|National Institute on Aging (NIA)	2013-12-20	Phase 2
NCT00633087	TERMINATED	Prostate Cancer	Rutgers, The State University of New Jersey	2006-11	PHASE1; PHASE2
NCT00707213	TERMINATED	Cancer	University of Utah	2007-08-21	PHASE1
NCT00109785	COMPLETED	Breast Cancer	Memorial Sloan Kettering Cancer Center	1997-03	PHASE1
NCT00096707	COMPLETED	Lung Cancer; Breast Cancer; Pancreatic Cancer; Head and Neck Cancer; Gastric Cancer	Threshold Pharmaceuticals	2004-02	PHASE1
NCT00247403	WITHDRAWN	Intracranial Neoplasms; Neoplasm Metastasis	University of Iowa	2005-10	PHASE1
NCT00385203	COMPLETED	Gastrointestinal Stromal Tumors; Soft Tissue Sarcomas	AstraZeneca	2006-09	PHASE2
NCT00201942	COMPLETED	Breast Cancer	Ontario Clinical Oncology Group (OCOG)	2005-02	PHASE3

(data from https://clinicaltrials.gov, updated on 2024-11-19)

Check the 2-DG (2-Deoxy-D-glucose) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a glucose analog, 2-Deoxy-D-glucose competitively inhibits hexokinase upon cellular uptake, disrupting glycolysis and reducing intracellular ATP production to induce cell cycle arrest and apoptosis in metabolically active cells. This glycolytic inhibition deprives rapidly proliferating cancer cells and hyperexcitable neural tissues of required metabolic energy, providing the mechanistic rationale for its clinical evaluation in solid tumors and neurological disorders such as epilepsy.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).